Giant cell arteritis (GCA) is the most common primary vasculitis in adults, an immune-mediated granulomatous vasculitis of medium and large vessels that primarily affects individuals ≥50 years old and carries a risk of irreversible vision loss in 15–20% of patients if untreated. [1-3] It is treated as a medical emergency requiring empiric high-dose glucocorticoids before confirmatory testing. [4-5]
The following figure from JAMA outlines the diagnostic algorithm for suspected GCA:
1. History
- New-onset headache — present in ~2/3 of patients; typically temporal, unilateral or bilateral, often described as boring or throbbing [6-7]
- Jaw claudication — pain with chewing that resolves with rest; one of the most specific symptoms (positive LR 4.90) [7]
- Visual symptoms — amaurosis fugax, diplopia, blurred vision, or sudden vision loss; visual loss is often painless and may be preceded by transient episodes [6][8]
- Scalp tenderness — pain when brushing hair or resting head on pillow [4]
- Constitutional symptoms — fatigue, weight loss, anorexia, fever, malaise; may be the predominant presentation [4][9]
- Proximal muscle pain/stiffness — polymyalgia rheumatica (PMR) symptoms overlap in 40–60% of GCA patients [10]
- Limb claudication — upper or lower extremity claudication from large-vessel involvement (positive LR 6.01, the highest of any symptom) [7]
- Timing: symptoms typically develop over weeks; ask about progression and any preceding PMR symptoms
- Important negatives: absence of trauma, no history of migraine or tension headache pattern, no infectious prodrome
2. Alarm Features
- Sudden vision loss or amaurosis fugax — ophthalmologic emergency; risk of bilateral blindness without treatment [6][11]
- Diplopia — may herald impending permanent vision loss [8]
- Jaw or tongue claudication — highly specific and associated with higher risk of ischemic complications [7][12]
- Scalp necrosis — rare but pathognomonic [12]
- Stroke or TIA symptoms — GCA causes stroke in ~7% of confirmed cases [5]
- Chest/back/abdominal pain — may indicate aortitis, aortic aneurysm, or dissection [8][13]
- Asymmetric blood pressures or absent pulses — suggests large-vessel involvement [8]
- Older age, jaw claudication, prior amaurosis fugax, and paradoxically lower inflammatory markers have been described as risk factors for vision loss [8]
3. Medications
- Initial treatment: High-dose oral prednisone 40–60 mg/day for uncomplicated GCA [4][9]
- IV methylprednisolone pulses (e.g., 1 g/day × 3 days): considered for vision loss or imminent vision-threatening disease [8]
- Tocilizumab (Actemra): FDA-approved glucocorticoid-sparing agent; 162 mg SC weekly (or every other week for new diagnosis/lower risk); conditionally recommended with glucocorticoids as initial therapy per ACR 2021 guidelines [9][14-15]
- Upadacitinib (Rinvoq): recently FDA-approved for GCA as an additional glucocorticoid-sparing option [8][16]
- Methotrexate: alternative steroid-sparing agent if tocilizumab is contraindicated or unavailable [9]
- Contraindications/cautions: Tocilizumab is generally avoided in patients with diverticulosis/diverticulitis (risk of GI perforation) and recurrent infections; tocilizumab suppresses CRP, making it unreliable for monitoring disease activity [14]
- Infliximab should NOT be used — associated with worse outcomes in GCA [5]
- Low-dose aspirin is sometimes considered for ischemic risk reduction, though evidence is limited
4. Diet
- No specific dietary triggers for GCA
- Calcium and vitamin D supplementation should be initiated with long-term glucocorticoid therapy to mitigate osteoporosis risk
- Adequate protein intake to counteract glucocorticoid-induced muscle wasting
- Sodium restriction may help manage glucocorticoid-induced fluid retention and hypertension
- Blood glucose monitoring and dietary counseling for steroid-induced hyperglycemia
5. Review of Systems
- Ophthalmologic: visual acuity changes, visual field deficits, diplopia, eye pain
- Neurologic: headache character/location, TIA/stroke symptoms, cognitive changes
- Musculoskeletal: proximal shoulder/hip girdle stiffness and pain (PMR overlap) [10]
- Vascular: limb claudication, Raynaud's phenomenon, pulse asymmetry
- Constitutional: fever, night sweats, weight loss, fatigue, anorexia
- Cardiovascular: chest pain, dyspnea (aortitis/aneurysm)
- ENT: jaw pain with chewing, tongue pain, dysphagia, sore throat
6. Collateral History and Family History
- Confirm symptom timeline and progression from family/caregivers, especially if visual or cognitive changes are present
- HLA-DRB104 alleles are associated with GCA susceptibility; a genetic link to Northern European descent is well established [9][17]
- Family history of autoimmune disease, vasculitis, or PMR may increase suspicion
- Social context: assess functional status, ability to self-administer medications, and support for long-term steroid management
7. Risk Factors
- Age ≥50 years (absolute requirement); peak incidence at 70–75 years [4][18]
- Female sex — women affected more than men (~2:1) [17]
- Northern European descent — highest incidence in Scandinavian populations [9]
- Polymyalgia rheumatica — 16–21% of PMR patients develop GCA [6][10]
- Smoking has been variably associated
- Infections (Mycoplasma, Chlamydia pneumoniae) have been suspected but not proven as triggers [17]
8. Differential Diagnosis
- Primary headache disorders (migraine, tension-type, cluster) — typically younger patients, no systemic inflammation
- ANCA-associated vasculitis — can mimic GCA on temporal artery biopsy; look for renal, pulmonary involvement and check ANCA [19]
- Non-arteritic anterior ischemic optic neuropathy (NAION) — vision loss without systemic inflammation; typically younger, associated with cardiovascular risk factors
- Atherosclerotic disease — temporal artery calcification can mimic GCA on exam
- Malignancy/lymphoma — can present with constitutional symptoms and elevated ESR
- Infection (endocarditis, osteomyelitis, abscess) — fever of unknown origin with elevated inflammatory markers
- IgG4-related disease — can cause temporal arteritis [19]
- Varicella-zoster virus (VZV) vasculopathy — arterial tropism, may trigger or mimic GCA [19]
- Takayasu arteritis — similar large-vessel vasculitis but typically age <50 [9]
- Primary CNS angiitis — younger patients, predominantly neurologic symptoms [5]
9. Past Medical History
- Prior episodes of PMR or GCA (relapse rate ~50%) [3]
- History of autoimmune conditions
- Cardiovascular disease (relevant for steroid side effects and aortic complications)
- Diabetes, osteoporosis, peptic ulcer disease (all impact glucocorticoid management)
- Diverticular disease (relative contraindication to tocilizumab) [14]
- Prior steroid use and adverse effects
- Surgical history: prior temporal artery biopsy, aortic surgery
10. Physical Exam
- Vital signs: fever (low-grade, present in a subset); check bilateral blood pressures for asymmetry [8]
- Temporal artery palpation: tenderness, thickening (positive LR 4.70), nodularity, loss of pulse (positive LR 3.25), prominence [7]
- Scalp tenderness on palpation (positive LR 3.14) [7]
- Ophthalmologic exam: visual acuity, visual fields by confrontation, pupillary response (RAPD), fundoscopy for pallid disc edema (arteritic AION), cotton-wool spots, or cherry-red spot (CRAO) [6][8]
- Vascular exam: auscultate for bruits (carotid, subclavian, axillary); palpate peripheral pulses
- Musculoskeletal: assess for proximal shoulder/hip girdle tenderness and limited range of motion (PMR)
- Neurologic: cranial nerve assessment, particularly CN II, III, IV, VI
11. Lab Studies
- ESR (Westergren): markedly elevated, typically >50 mm/hr (sensitivity ~80%; ESR >40 has negative LR 0.18, making a normal ESR helpful in reducing suspicion) [7][20]
- CRP: elevated in ~96% of cases (sensitivity 96% in one population-based study); CRP ≥2.5 mg/dL has negative LR 0.38 [7][20]
- Combined ESR + CRP: both normal in only ~3–4% of biopsy-proven GCA — a normal ESR AND CRP substantially reduces but does not exclude the diagnosis [20-21]
- CBC: thrombocytosis (platelets >400 × 10³/μL, positive LR 3.75); normocytic anemia common [7]
- CMP: baseline hepatic/renal function (pre-steroid and pre-tocilizumab)
- IL-6: consider when ESR/CRP are normal but clinical suspicion remains high [4]
- ANCA, blood cultures, serum protein electrophoresis: to rule out mimics when clinically indicated [21]
The following table from a JAMA Internal Medicine meta-analysis summarizes the diagnostic accuracy of key physical and laboratory findings:
12. Imaging
- Color duplex ultrasonography of temporal arteries: first-line imaging in many centers; the "halo sign" (hypoechoic ring around the arterial lumen) is the most specific finding. Should ideally be performed within 7 days of starting steroids, as sensitivity decreases with treatment [2][6]
- Temporal artery biopsy (TAB): remains the gold standard for cranial GCA; specimen ≥1 cm recommended; should be performed within 2 weeks of starting steroids (histology may remain positive for weeks). Negative biopsy does not exclude GCA due to skip lesions (false-negative rate up to 44% with prior steroid treatment) [2][4][6]
- MRI of temporal/cranial arteries: alternative when ultrasound is unavailable; can show mural enhancement and edema
- FDG-PET/CT: useful for detecting large-vessel (extracranial) involvement; assesses aortic and branch vessel inflammation [6][9]
- CT angiography: evaluates for aortic aneurysm, stenosis, or dissection in patients with large-vessel symptoms
- Imaging is unnecessary if clinical presentation and biopsy are concordant
13. Special Tests
- ACR 1990 Classification Criteria (≥3 of 5): age ≥50, new headache, temporal artery abnormality, ESR ≥50, abnormal TAB — sensitivity 93.5%, specificity 91.2% [2]
- 2022 ACR/EULAR Classification Criteria: points-based system (≥6 points); includes imaging findings (halo sign +5, FDG-PET aortic activity +2), biopsy (+5), ESR ≥50 or CRP ≥10 (+3), sudden visual loss (+3), jaw/tongue claudication (+2), and others — sensitivity 87%, specificity 94.8% [18]
- Temporal artery biopsy: histopathology shows granulomatous inflammation with mononuclear cell infiltrate, intimal hyperplasia, fragmentation of internal elastic lamina, and multinucleated giant cells (present in ~50% of positive biopsies)
- Point-of-care ultrasound: increasingly used in ED and fast-track clinics for rapid halo sign assessment [11]
14. ECG
- ECG is not a primary diagnostic tool for GCA
- Consider ECG if chest pain, dyspnea, or hemodynamic instability is present (to evaluate for aortic dissection complications, pericarditis, or concurrent cardiac disease)
- No specific ECG pattern is associated with GCA
- Baseline ECG is reasonable before initiating high-dose steroids in elderly patients with cardiovascular comorbidities
15. Assessment
GCA is a medical emergency due to the risk of irreversible blindness. [2] Two major phenotypes are recognized: cranial GCA (headache, jaw claudication, visual symptoms, temporal artery abnormalities) and large-vessel GCA (aortitis, limb claudication, vascular stenosis/aneurysm); these often coexist. [8] Approximately 40–60% of GCA patients also have PMR. [10]
Severity stratification:
- Vision-threatening: any visual symptoms (amaurosis fugax, diplopia, vision loss) → highest urgency
- Cranial without visual symptoms: headache, jaw claudication, scalp tenderness → urgent
- Systemic/large-vessel predominant: constitutional symptoms, limb claudication, aortitis → urgent but may have more insidious onset
Atypical presentations include fever of unknown origin, isolated PMR, occult large-vessel disease without cranial symptoms, and tongue/scalp necrosis. [8][12] Complications include permanent bilateral blindness, stroke (~7%), aortic aneurysm/dissection (18% in long-term follow-up), and glucocorticoid-related morbidity (>80% of patients). [2][5][13]
16. Treatment Plan
Initial stabilization (ED):
- Do not delay steroids for biopsy or imaging [1][5]
- Without visual symptoms: Prednisone 40–60 mg/day orally [4][9]
- With visual symptoms or vision loss: IV methylprednisolone 1 g/day × 3 days, then transition to oral prednisone 60 mg/day [8]
- Urgent ophthalmology and rheumatology consultation [1]
Glucocorticoid-sparing therapy (initiated by rheumatology):
- Tocilizumab 162 mg SC weekly — conditionally recommended with glucocorticoids as initial therapy; GiACTA trial showed 56% sustained remission at 52 weeks vs. 18% with prednisone alone [9][14-15]
- Upadacitinib 15 mg daily — recently approved alternative [8][16]
- Methotrexate 7.5–15 mg/week — if tocilizumab/upadacitinib contraindicated [9]
Glucocorticoid taper (per AAFP/ACR guidance):
- Taper prednisone by 10–20% per month while monitoring ESR/CRP
- When dose <10 mg/day, taper by 1 mg/month
- Total treatment duration typically 1–5 years; aim for 0–5 mg/day by 12 months [4][8]
Supportive care: PPI for GI prophylaxis, calcium/vitamin D, bone density monitoring, glucose monitoring, PJP prophylaxis if prolonged high-dose steroids
The following table summarizes the treatment approach:
17. Disposition
- Admit if: active vision loss, need for IV methylprednisolone, stroke/TIA, suspected aortic dissection, significant comorbidities complicating high-dose steroid initiation, or inability to ensure close follow-up
- Observation/ED discharge with close follow-up if: no visual symptoms, steroids initiated, reliable patient, rheumatology/ophthalmology follow-up arranged within 24–72 hours
- Specialist consultation triggers: all suspected GCA patients warrant rheumatology referral; ophthalmology consultation is urgent for any visual symptoms; vascular surgery if aortic aneurysm/dissection is identified [1][9]
- Temporal artery biopsy should be arranged within 2 weeks of starting steroids (does not need to delay treatment) [6]
18. Follow Up / Return Precautions
- Follow-up timing: Rheumatology within 1–2 weeks; ophthalmology within 24–72 hours if visual symptoms; primary care within 1 week for steroid monitoring
- Return immediately for: any new or worsening visual changes, sudden vision loss in either eye, new severe headache, jaw claudication, limb weakness/numbness, chest or back pain, syncope
- Long-term monitoring: ESR/CRP at each visit during taper; glucose, blood pressure, bone density; screen for aortic aneurysm with imaging (CT or MRI of chest/abdomen) — patients require long-term aortic surveillance even after therapy is discontinued [3][13]
- Expected course: symptoms typically improve dramatically within 24–72 hours of starting steroids; failure to respond should prompt reconsideration of the diagnosis [4]
- Relapse rate: ~50% of patients experience relapse, most commonly during steroid taper; relapses tend to be minor (PMR symptoms) but ~25% are major (ischemic symptoms) [3][8]
- Counsel patients on steroid side effects, importance of adherence, and not to abruptly discontinue steroids
References
1. High Risk and Low Prevalence Diseases: Giant Cell Arteritis. — Lacy A, Nelson R, Koyfman A, Long B. The American Journal of Emergency Medicine. 2022.
2. High Risk and Low Prevalence Diseases: Giant Cell Arteritis. — Lacy A, Nelson R, Koyfman A, Long B. The American Journal of Emergency Medicine. 2022.
3. High Risk and Low Prevalence Diseases: Giant Cell Arteritis. — Lacy A, Nelson R, Koyfman A, Long B. The American Journal of Emergency Medicine. 2022.
4. Halo Sign on Temporal Artery Ultrasound Versus Temporal Artery Biopsy for Giant Cell Arteritis. — Pouncey AL, Yeldham G, Magan T, et al. The Cochrane Database of Systematic Reviews. 2024.
5. Halo Sign on Temporal Artery Ultrasound Versus Temporal Artery Biopsy for Giant Cell Arteritis. — Pouncey AL, Yeldham G, Magan T, et al. The Cochrane Database of Systematic Reviews. 2024.
6. Giant Cell Arteritis. — Kermani TA. Annals of Internal Medicine. 2026.
7. Giant Cell Arteritis. — Kermani TA. Annals of Internal Medicine. 2026.
8. Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review. — Raleigh MF, Stoddard J, Darrow HJ. American Family Physician. 2022.
9. Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review. — Raleigh MF, Stoddard J, Darrow HJ. American Family Physician. 2022.
10. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. — Kleindorfer DO, Towfighi A, Chaturvedi S, et al. Stroke. 2021.
11. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. — Kleindorfer DO, Towfighi A, Chaturvedi S, et al. Stroke. 2021.
12. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. — Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. The Journal of the American Medical Association. 2016.
13. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review. — Buttgereit F, Dejaco C, Matteson EL, Dasgupta B. The Journal of the American Medical Association. 2016.
14. Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis. — van der Geest KSM, Sandovici M, Brouwer E, Mackie SL. JAMA Internal Medicine. 2020.
15. Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis. — van der Geest KSM, Sandovici M, Brouwer E, Mackie SL. JAMA Internal Medicine. 2020.
16. Large-Vessel Vasculitis. — Cacoub P, Vieira M, Langford CA, Tazi Mezalek Z, Saadoun D. Lancet. 2025.
17. Large-Vessel Vasculitis. — Cacoub P, Vieira M, Langford CA, Tazi Mezalek Z, Saadoun D. Lancet. 2025.
18. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. — Maz M, Chung SA, Abril A, et al. Arthritis Care & Research. 2021.
19. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. — Maz M, Chung SA, Abril A, et al. Arthritis Care & Research. 2021.
20. Polymyalgia Rheumatica. — Espígol-Frigolé G, Dejaco C, Mackie SL, et al. Lancet. 2023.
21. Polymyalgia Rheumatica. — Espígol-Frigolé G, Dejaco C, Mackie SL, et al. Lancet. 2023.
22. Advances in Diagnosing and Treating Giant Cell Arteritis: New Hope for Arteritic Anterior Ischemic Optic Neuropathy. — von der Emde L, Petzinna SM, Herwig-Carl MC, et al. Survey of Ophthalmology. 2025.
23. Advances in Diagnosing and Treating Giant Cell Arteritis: New Hope for Arteritic Anterior Ischemic Optic Neuropathy. — von der Emde L, Petzinna SM, Herwig-Carl MC, et al. Survey of Ophthalmology. 2025.
24. A Glossary of Signs and Symptoms of Giant Cell Arteritis. — Soowamber ML, Bond M, Touma Z, et al. Annals of the Rheumatic Diseases. 2025.
25. A Glossary of Signs and Symptoms of Giant Cell Arteritis. — Soowamber ML, Bond M, Touma Z, et al. Annals of the Rheumatic Diseases. 2025.
26. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. — Hiratzka LF, Bakris GL, Beckman JA, et al. Journal of the American College of Cardiology. 2010.
27. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM Guidelines for the Diagnosis and Management of Patients With Thoracic Aortic Disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology,American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons,and Society for Vascular Medicine. — Hiratzka LF, Bakris GL, Beckman JA, et al. Journal of the American College of Cardiology. 2010.
28. Inflammatory Diseases of the Aorta: JACC Focus Seminar, Part 2. — Kadian-Dodov D, Seo P, Robson PM, Fayad ZA, Olin JW. Journal of the American College of Cardiology. 2022.
29. Inflammatory Diseases of the Aorta: JACC Focus Seminar, Part 2. — Kadian-Dodov D, Seo P, Robson PM, Fayad ZA, Olin JW. Journal of the American College of Cardiology. 2022.
30. FDA Drug Label. — Updated date: 2025-12-16. Food and Drug Administration.
31. FDA Drug Label. — Updated date: 2025-12-16. Food and Drug Administration.
32. FDA Orange Book. — FDA Orange Book. 2026.
33. FDA Orange Book. — FDA Orange Book. 2026.
34. The neutrophil: A key resourceful agent in immune‐mediated vasculitis. — Aymonnier K, Amsler J, Lamprecht P, Salama A, Witko-Sarsat V. Immunological Reviews. 2023.
35. The neutrophil: A key resourceful agent in immune‐mediated vasculitis. — Aymonnier K, Amsler J, Lamprecht P, Salama A, Witko-Sarsat V. Immunological Reviews. 2023.
36. 2022 American College of Rheumatology/Eular Classification Criteria for Giant Cell Arteritis. — Ponte C, Grayson PC, Robson JC, et al. Arthritis & Rheumatology. 2022.
37. 2022 American College of Rheumatology/Eular Classification Criteria for Giant Cell Arteritis. — Ponte C, Grayson PC, Robson JC, et al. Arthritis & Rheumatology. 2022.
38. Temporal Artery Vascular Diseases. — Greigert H, Ramon A, Tarris G, et al. Journal of Clinical Medicine. 2022.
39. Temporal Artery Vascular Diseases. — Greigert H, Ramon A, Tarris G, et al. Journal of Clinical Medicine. 2022.
40. Population-Based Performance of Inflammatory Markers in Giant Cell Arteritis. — Castillejo Becerra CM, Crowson CS, Langenfeld HE, et al. American Journal of Ophthalmology. 2025.
41. Population-Based Performance of Inflammatory Markers in Giant Cell Arteritis. — Castillejo Becerra CM, Crowson CS, Langenfeld HE, et al. American Journal of Ophthalmology. 2025.
42. Giant-Cell Arteritis and Polymyalgia Rheumatica. — Weyand CM, Goronzy JJ. The New England Journal of Medicine. 2014.
43. Giant-Cell Arteritis and Polymyalgia Rheumatica. — Weyand CM, Goronzy JJ. The New England Journal of Medicine. 2014.